Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 5/20 | 0.47 |
| ▸ | MMP1 | P03956 | 4/20 | 0.47 |
| ▸ | MMP8 | P22894 | 4/20 | 0.46 |
| ▸ | MMP9 | P14780 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15684087 | 1.00 | L3MBTL1 (0.51) | L3MBTL1PPARAMMP3MMP1MMP8 | |
| SCHEMBL7422742 | 0.96 | L3MBTL1 (0.53) | L3MBTL1PPARAMMP3MMP1MMP8 | |
| SCHEMBL2410580 | 0.94 | PPARA (0.49) | L3MBTL1PPARAMMP3MMP1MMP8 | |
| SCHEMBL2410585 | 0.94 | PPARA (0.49) | L3MBTL1PPARAMMP3MMP1MMP8 | |
| SCHEMBL17756152 | 0.94 | PPARA (0.49) | L3MBTL1PPARAMMP3MMP1MMP8 | |
| SCHEMBL7475848 | 0.87 | CTSL (0.41) | L3MBTL1PPARAMMP3MMP1MMP8 | |
| SCHEMBL15684088 | 0.86 | L3MBTL1 (0.50) | L3MBTL1PPARAMMP3MMP1MMP8 | |
| SCHEMBL17755918 | 0.86 | L3MBTL1 (0.46) | L3MBTL1PPARAMMP3MMP1MMP8 | |
| SCHEMBL17755935 | 0.85 | L3MBTL1 (0.47) | L3MBTL1PPARAMMP3MMP1MMP8 | |
| SCHEMBL17755916 | 0.85 | L3MBTL1 (0.47) | L3MBTL1PPARAMMP3MMP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2927217-B1 | AMIDE COMPOUND AND PHARMACEUTICAL APPLICATION THEREFOR | JAPAN TOBACCO INC (JP) | 2018-01-17 | — | — | EP | disclosed |
| EP-2927217-B1 | AMIDE COMPOUND AND PHARMACEUTICAL APPLICATION THEREFOR | JAPAN TOBACCO INC (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20160346256-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-12-01 | — | — | US | disclosed |
| US-20160346256-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-12-01 | — | — | US | disclosed |
| US-20160346256-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2016-12-01 | — | — | US | disclosed |
| EP-2927217-A1 | Amide compound and pharmaceutical application therefor | Japan Tobacco Inc. (JP) | 2015-10-07 | — | — | EP | disclosed |
| EP-2927217-A1 | Amide compound and pharmaceutical application therefor | Japan Tobacco Inc. (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20140296306-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296306-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2014-10-02 | — | — | US | disclosed |
| US-20140296306-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2719690-A1 | AMIDE COMPOUND AND PHARMACEUTICAL APPLICATION THEREFOR | Japan Tobacco Inc. (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8604069-B2 | Amide compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120322837-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2012-12-20 | — | — | US | disclosed |
| US-20120322837-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2012-12-20 | — | — | US | disclosed |
| US-20120322837-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346256-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | SLC10A2, SLC10A1, SLC5A11 | L3MBTL1 4474/4885PPARA 303/4885MMP3 2718/4885 |
| US-20120322837-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | SLC10A2, SLC10A1, SLC5A11 | L3MBTL1 4474/4885PPARA 303/4885MMP3 2718/4885 |
| US-20140296306-A1 | AMIDE COMPOUND AND MEDICINAL USE THEREOF | SLC10A2, SLC10A1, SLC5A11 | L3MBTL1 4474/4885PPARA 303/4885MMP3 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.